These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 17665482)

  • 1. Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis.
    Bansback N; Marra C; Tsuchiya A; Anis A; Guh D; Hammond T; Brazier J
    Arthritis Rheum; 2007 Aug; 57(6):963-71. PubMed ID: 17665482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the validity of estimating EQ-5D and SF-6D utility values from the health assessment questionnaire in patients with inflammatory arthritis.
    Harrison MJ; Lunt M; Verstappen SM; Watson KD; Bansback NJ; Symmons DP
    Health Qual Life Outcomes; 2010 Feb; 8():21. PubMed ID: 20149253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
    Adams R; Walsh C; Veale D; Bresnihan B; FitzGerald O; Barry M
    Pharmacoeconomics; 2010; 28(6):477-87. PubMed ID: 20465316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
    Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
    Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis.
    Wolfe F; Michaud K; Wallenstein G
    J Rheumatol; 2010 Aug; 37(8):1615-25. PubMed ID: 20551106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.
    Kim HL; Kim D; Jang EJ; Lee MY; Song HJ; Park SY; Cho SK; Sung YK; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim J; Kim SK; Kim TH; Kim TJ; Koh E; Lee H; Lee HS; Lee J; Lee SS; Lee SW; Park SH; Shim SC; Yoo DH; Yoon BY; Bae SC; Lee EK
    Rheumatol Int; 2016 Apr; 36(4):505-13. PubMed ID: 26849891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis.
    Amjadi SS; Maranian PM; Paulus HE; Kaplan RM; Ranganath VK; Furst DE; Khanna PP; Khanna D;
    J Rheumatol; 2009 Jun; 36(6):1150-7. PubMed ID: 19369459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain.
    Carreño A; Fernández I; Badia X; Varela C; Roset M
    Value Health; 2011 Jan; 14(1):192-200. PubMed ID: 21211502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An empirical evaluation of the SF-12, SF-6D, EQ-5D and Michigan Hand Outcome Questionnaire in patients with rheumatoid arthritis of the hand.
    Dritsaki M; Petrou S; Williams M; Lamb SE
    Health Qual Life Outcomes; 2017 Jan; 15(1):20. PubMed ID: 28118833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?
    Marra CA; Rashidi AA; Guh D; Kopec JA; Abrahamowicz M; Esdaile JM; Brazier JE; Fortin PR; Anis AH
    Qual Life Res; 2005 Jun; 14(5):1333-44. PubMed ID: 16047508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis.
    Lillegraven S; Kristiansen IS; Kvien TK
    Ann Rheum Dis; 2010 Oct; 69(10):1762-7. PubMed ID: 20448285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry.
    Buitinga L; Braakman-Jansen LM; Taal E; Kievit W; Visser H; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):826-32. PubMed ID: 22262513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting EQ-5D-US and SF-6D societal health state values from the Osteoporosis Assessment Questionnaire.
    McDonough CM; Grove MR; Elledge AD; Tosteson AN
    Osteoporos Int; 2012 Feb; 23(2):723-32. PubMed ID: 21484360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol.
    Ariza-Ariza R; Hernández-Cruz B; Carmona L; Dolores Ruiz-Montesinos M; Ballina J; Navarro-Sarabia F;
    Arthritis Rheum; 2006 Oct; 55(5):751-6. PubMed ID: 17013822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the psychometric properties of generic utility measures in multiple sclerosis.
    Kuspinar A; Mayo NE
    Pharmacoeconomics; 2014 Aug; 32(8):759-73. PubMed ID: 24846760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the EQ-5D and the SF-6D utility measures in 813 patients with early arthritis: results from the ESPOIR cohort.
    Gaujoux-Viala C; Rat AC; Guillemin F; Flipo RM; Fardellone P; Bourgeois P; Fautrel B
    J Rheumatol; 2011 Aug; 38(8):1576-84. PubMed ID: 21532054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
    Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
    Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.